Alzheimer’s disease is a neurodegenerative disorder that currently affects an estimated 45 million people worldwide. As the global population ages, especially in developed economies, the prevalence of Alzheimer’s and other forms of dementia is rising significantly. By 2050, the number of people living with dementia worldwide is projected to triple and reach 152 million. The rising geriatric population, coupled with increased life expectancy, is the major driver of the global Alzheimer’s disease therapeutics market. Alzheimer’s drugs are medications that are used to slow down the progression of Alzheimer’s disease and relieve its symptoms. The most common Alzheimer’s drugs approved by regulatory agencies includeNamzaric, Exelon, Aricept, Razadyne, and Nuedexta. These drugs work by enhancing the neurotransmitter acetylcholine in the brain and by stabilizing levels of other neurotransmitters like dopamine and norepinephrine. As the disease progresses, these medications temporarily help cognitive functions like memory and thinking get better or stay the same for a limited period of time. The global Alzheimer’s Drugs Market is estimated to be valued at US$ 4.86 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024-2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: One of the major trends witnessed in the global Alzheimer’s drugs market is the rising focus on combination therapy. Traditionally, monotherapies were the standard of care for Alzheimer’s disease. However, combination therapies targeting multiple pathways implicated in disease pathology are gaining favor. For instance, companies are evaluating drugs combining NMDA receptor antagonists with acetylcholinesterase inhibitors. Combination therapies hold promise to more effectively manage symptoms and potentially slow disease progression compared to single pathway targeting drugs. Ongoing research aims to establish combination therapies as a more efficacious treatment paradigm for Alzheimer’s disease. Porter’s Analysis Threat of new entrants: The threat of new entrants in the Alzheimer’s Drugs Market is moderate due to the need for extensive R&D and resources required for drug development. Bargaining power of buyers: The bargaining power of buyers is moderate due to the availability of substitute drugs and treatment options. Bargaining power of suppliers: The bargaining power of suppliers is moderate since there are many raw material suppliers available. Threat of new substitutes: The threat of new substitutes is high as research continues for better treatment options. Competitive rivalry: The competitive rivalry is high among existing players to develop new drugs with better efficacy and safety. Key Takeaways The global Alzheimer’s Drugs Market Share is expected to witness high growth over the forecast period of 2023 to 2030. Regional analysis reveals that North America currently dominates the market owing to high awareness and healthcare expenditure. Europe is also a major market boosted by supportive reimbursement policies. Asia Pacific is expected to be the fastest growing region on account of rising aging population and increasing healthcare spending. Key players operating in the Alzheimer’s Drugs market are AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Clovis Oncology, Inc., and Tesaro (acquired by GlaxoSmithKline). AstraZeneca’s drug BAN2401 and Pfizer Inc.’s drug aducanumab are some of the key pipeline products that are under development and have potential to capture significant market share. Collaborations between pharmaceutical companies and clinical research organizations are also expected to aid market growth over the forecast period.
by Alzheimer’s disease is a progressive neurological disorder that slowly destroys memory and thinking skills. It is the most common cause of dementia – a group …